The natural GLP-1 trigger
Curbisol™ naturally stimulates the combined release of the body’s own satiety hormones, GLP-1 and CCK, sending a prolonged satiety signal to the brain without the crash effect of stimulants.
Backed by extensive clinical data (Montelius et al., 2014; Saeidi et al., 2023), it acts fast, directly targets head-hunger and lowers sweet cravings by up to 40%. Curbisol™ is a high-potency, dose-dependent satiety engine for intensive weight management lines and for brands addressing consumers looking for natural weight-loss solutions.
Curbisol™ vs placebo
This comparison shows Curbisol™ results in two 12-week, placebo-controlled clinical trials:
| Feature | Placebo | Curbisol™ | The Curbisol™ advantage |
| Total weight loss (overweight women) | −4.36% body weight | −5.0 kg (−6.3% body weight) | +1.5 kg extra weight loss (+43–45%) |
| Weight loss without exercise (obese men) | Baseline | −2.15 kg | +175% vs placebo |
| Weight loss with functional exercise (obese men) | −3.59 kg | −6.88 kg (−7.31% body weight) | +91.6% exercise efficacy |
| Daily sweet snacking urges | Baseline | −38% to −40% | Reduced hedonic hunger |
| GLP-1 release | Baseline | +160% at peak, Day 1 | Endogenous satiety activation |
The 3 core superpowers of Curbisol™
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Multi-hormone satiety activation
Curbisol™ naturally activates the body’s own satiety hormones, sending a prolonged satiety signal to the brain.
GLP-1 (the satiety signal)
Stimulates GLP-1 release by +160% at peak, from Day 1.
CCK (the fullness trigger)
Combined release of cholecystokinin (CCK) alongside GLP-1 for a dual endogenous activation.
No crash effect
A double activation of the body’s own hormones, without the crash effect of stimulants.
Craving control
Curbisol™ acts on “hedonic hunger”: the urge to eat for pleasure rather than need.
Sweet cravings
Reduces the daily urge to snack on sweet foods by nearly 40%.
7 hours of active defense
– 95% sugar cravings and – 87% chocolate cravings. [à valider, voir point 2]
Head-hunger
Acts fast, directly targeting impulsive, emotional and sugar-driven snacking.
Weight loss & metabolic support
Validated in two 12-week clinical trials, with or without exercise.
Documented weight loss
5.0 kg (11 lbs) lost on average in overweight women, more than 6.2% of total body mass.
Effort multiplier
6.88 kg (15.1 lbs) lost with functional exercise vs 3.59 kg for exercise alone: +91.6% efficacy.
Adipokine regulation
Reduces pro-inflammatory adipokines (leptin, resistin, vaspin) and increases beneficial adipokines (adiponectin, omentin).
Glycemic balance
Significant reduction in fasting blood glucose, circulating insulin and insulin resistance (HOMA-IR).
The formulation advantage
A high-potency, dose-dependent satiety engine, designed as the clinical anchor of intensive weight management lines. In clinical use, Curbisol™ was taken 30 minutes before lunch.
Backed by science
Clinically validated
2 Placebo-controlled 12-week clinical trials, in overweight women and obese men
%
+160% GLP-1 at peak from Day 1, with combined CCK release
Clinical references:
- Montelius C., et al. (2014): 12-week trial in overweight women
- Saeidi A., et al. (2023): 12-week trial in obese men, with and without exercise
- Köhnke R., et al. (2009): GLP-1 and CCK release
- Stenblom E.L., et al. (2015): sweet cravings and hedonic hunger
These statements have not been evaluated by the Swissmedic or Food and Drug Administration. Curbisol™ is not intended to diagnose, treat, cure, or prevent any disease.